NOTE 5 - CAPITAL STOCK	3 Months Ended
Mar. 31, 2020
Notes
NOTE 5 - CAPITAL STOCK	NOTE 5 – CAPITAL STOCK The Company has authorized 100,000,000 shares of common shares with a par value of $0.0001 per shares and 20,000,000 shares of preferred stock, with a par value of $0.0001 per shares. Pursuant to the resolution of the shareholders meeting held on March 30, 2015 the Company designated 500,000 shares of the preferred authorized shares as preferred shares – Series “B” shares. The preferred shares – Series “B” were assigned the following preferences: `a)`Each share to carry one vote. `b)`Each share will be redeemable with a 365 days written notice to the company. `c)`Each share will be junior to any debt incurred by the Company. `d)`The redemption value will be the par value at which such “preferred shares – series B” are bought by the subscriber. `e)`Each share will carry a dividend right at par with the common shares. On December 31, 2014 the Company had a Note outstanding in the principal amount of $330,000 plus interest payable to GS Pharmaceuticals, Inc. By mutual consent this note and accrued interest was converted to 330,000 preferred shares – Series “B”. On March 31, 2015 an amount of $58,000 was subscribed by Redfield Holdings, Ltd. by cancellation of a Note against the issuance of 9,700 shares of preferred shares – Series “A”. These shares were issued to Redfield Holding, Ltd. thus making a total of entire designated preferred shares – Series “A” shares to Redfield Holdings, Ltd. Each share of preferred shares – Series “A” carries voting right equal to 10,000 common shares. On March 31, 2017 total preferred shares issued and outstanding are 10,000 Series “A” and 330,000 Series “B”. On December 31, 2018 the Company had a Note outstanding in the principal amount of $470,935; by mutual consent this note and accrued interest was converted to 470,935 preferred shares - Series “C”. On April 2, 2019, the Company accepted subscription in the amount of $14,490 against issuance of 21,000 common shares this bringing the total number of common shares issued and outstanding to 26,221,000.

NOTE 5 - CAPITAL STOCK

3 Months Ended

Mar. 31, 2020

NOTE 5 – CAPITAL STOCK

The Company has authorized 100,000,000 shares of common shares with a par value of $0.0001 per shares and 20,000,000 shares of preferred stock, with a par value of $0.0001 per shares.

Pursuant to the resolution of the shareholders meeting held on March 30, 2015 the Company designated 500,000 shares of the preferred authorized shares as preferred shares – Series “B” shares. The preferred shares – Series “B” were assigned the following preferences:

a)Each share to carry one vote.

b)Each share will be redeemable with a 365 days written notice to the company.

c)Each share will be junior to any debt incurred by the Company.

d)The redemption value will be the par value at which such “preferred shares – series B” are bought by the subscriber.

e)Each share will carry a dividend right at par with the common shares.

On December 31, 2014 the Company had a Note outstanding in the principal amount of $330,000 plus interest payable to GS Pharmaceuticals, Inc. By mutual consent this note and accrued interest was converted to 330,000 preferred shares – Series “B”.

On March 31, 2015 an amount of $58,000 was subscribed by Redfield Holdings, Ltd. by cancellation of a Note against the issuance of 9,700 shares of preferred shares – Series “A”. These shares were issued to Redfield Holding, Ltd. thus making a total of entire designated preferred shares – Series “A” shares to Redfield Holdings, Ltd. Each share of preferred shares – Series “A” carries voting right equal to 10,000 common shares.

On March 31, 2017 total preferred shares issued and outstanding are 10,000 Series “A” and 330,000 Series “B”.

On December 31, 2018 the Company had a Note outstanding in the principal amount of $470,935; by mutual consent this note and accrued interest was converted to 470,935 preferred shares - Series “C”.

On April 2, 2019, the Company accepted subscription in the amount of $14,490 against issuance of 21,000 common shares this bringing the total number of common shares issued and outstanding to 26,221,000.